Reuters logo
9 months ago
BRIEF-Insys Therapeutics reports preliminary estimated revenues from Subsys for Q3 2016 to be $54 mln -$55 mln
October 13, 2016 / 11:02 AM / 9 months ago

BRIEF-Insys Therapeutics reports preliminary estimated revenues from Subsys for Q3 2016 to be $54 mln -$55 mln

1 Min Read

Oct 13 (Reuters) - Insys Therapeutics Inc :

* Insys Therapeutics reports preliminary estimated revenues from subsys for the third quarter 2016

* Insys Therapeutics Inc - preliminary estimated revenues from Subsys (fentanyl sublingual spray) for Q3 of 2016 will be in range of $54 million to $55 million

* Insys Therapeutics Inc- company believes it will be cash-flow positive at the level of sales

* Insys Therapeutics Inc - "estimated revenues for quarter reflect a decline in prescriptions"

* Insys Therapeutics-believes scrutiny resulted in patients having difficulty getting reimbursement for transmucosal immediate release fentanyl medications Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below